Esomeprazole vs Rabeprazole
## Overview
Esomeprazole achieves the highest plasma concentrations among PPIs; rabeprazole has the most rapid parietal cell activation and least CYP2C19 dependence. Both are effective for severe acid-related disorders.
## Mechanism of Action
Both irreversibly inhibit H+/K+-ATPase. Rabeprazole's chemical structure allows faster activation in the parietal cell canaliculus, whereas esomeprazole's advantage is higher bioavailability as a pure S-enantiomer.
## Pharmacokinetics
Esomeprazole: CYP2C19 primary, high AUC. Rabeprazole: primarily non-enzymatic hydrolysis, minimal CYP2C19 dependence.
## Clinical Considerations
Rabeprazole is preferred in CYP2C19 ultra-rapid metabolizers. In triple therapy for H. pylori eradication, rabeprazole-based regimens show high eradication rates across genotypes due to its consistent exposure. Esomeprazole achieves equivalent results in normal/poor metabolizers.
## Key Takeaways
- Both effective; choice often guided by CYP2C19 status
- Rabeprazole: CYP2C19-independent, preferred in ultra-rapid metabolizers
- Esomeprazole: highest AUC, preferred when maximum acid suppression needed
Fazit
Rabeprazole is preferred in patients with CYP2C19 ultra-rapid metabolizer status or East Asian populations with high CYP2C19 UM prevalence. Esomeprazole is preferred for maximum acid suppression in refractory GERD or Zollinger-Ellison syndrome.